IPAR

Public Assessment Report for a
Medicinal Product for Human Use

Scientific Discussion

Prucalopride 1 mg film-coated tablets
Prucalopride
PA0688/066/001

The Public Assessment Report reflects the scientific conclusion reached by the Health Products Regulatory Authority (HPRA) at the end of the evaluation process and provides a summary of the grounds for approval of a marketing authorisation for a specific medicinal product for human use. It is made available by the HPRA for information to the public, after deletion of commercially sensitive information. The legal basis for its creation and availability is contained in Article 21 of Directive 2001/83/EC, as amended. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the medicinal product for marketing in Ireland.

CONTENTS

I. INTRODUCTION

Based on the review of the data on quality, safety and efficacy, the HPRA has granted a marketing authorisation for Prucalopride 1 mg and 2 mg film-coated tablets, from Chanelle Medical on June 26th 2020.

With Ireland as the Reference Member State in this Decentralised Procedure, Chanelle Medical applied for the Marketing Authorisations for Prucalopride 1 mg and 2 mg film-coated tablets in IE/H/0603/001-002/DC with CMS DE

The application was made according to the provisions of Article 10(1) of Directive 2001/83/EC.

This medicinal product is a generic version of the originator product Resolor 1mg and 2mg film-coated tablets film-coated tablets marketed by Shire Pharmaceuticals Ireland Limited, authorised by a centralised procedure EMEA/H/C/001012 and registered since 15th of October 2009.

No scientific advice has been given to the applicant with respect to these products.

The prescription status of the products is "subject to medical prescription"

The Summary of Product Characteristics for (SmPC) for this medicinal product is available on the HPRA's website.

Name of the product	Prucalopride 1 mg film-coated tablets Prucalopride 2 mg film-coated tablets
Name(s) of the active substance(s) (INN)	Prucalopride Succinate
Pharmacotherapeutic classification (ATC code)	A06AX05
Pharmaceutical form and strength(s)	Film-coated tablet; 1 mg, 2 mg
Marketing Authorisation Number(s) in Ireland (PA)	PA0688/066/001-002
Marketing Authorisation Holder	Chanelle Medical
MRP/DCP No.	IE/H/0603/001-002/DC
Reference Member State	IE
Concerned Member State	DE

II. QUALITY ASPECTS

This application is for Prucalopride 1 mg and 2 mg film-coated tablets.

II.2 Drug substance

The active substance is Prucalopride succinate, an established active substance not described in the European Pharmacopoeia, and is manufactured in accordance with the principles of Good Manufacturing Practice (GMP).

The active substance specification is considered adequate to control the quality and meets current pharmacopoeial requirements. Batch analytical data demonstrating compliance with this specification has been provided.

II.3 Medicinal product

P.1 Composition

The excipients in the medicinal product are listed in section 6.1 of the SmPC.
A visual description of the product is included in section 3 of the SmPC.

P.2 Pharmaceutical Development

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

P.3 Manufacture of the Product

The product is manufactured in accordance with the principles of good manufacturing practice (GMP) at suitably qualified manufacturing sites.

The manufacturing process has been validated according to relevant European guidelines and the process is considered to be sufficiently validated.

P.4 Control of Other Substances (Excipients/*Ancillary Substances*)

All ingredients comply with Ph. Eur. or are adequately controlled by the manufacturer's specifications.

P.5 Control of Finished Product

The Finished Product Specification is based on the pharmacopoeial monograph for tablets, and the tests and control limits are considered appropriate for this type of product.

The analytical methods used are described in sufficient detail and are supported by validation data.

Batch analytical data for a number of batches from the proposed production site have been provided, and demonstrate the ability of the manufacturer to produce batches of finished product of consistent quality.

P.7 Packaging material

The approved packaging for this product is described in section 6.5 of the SmPC.

Evidence has been provided that the packaging complies with Ph. Eur./EU legislation for use with foodstuffs requirements.

P.8 Stability of the Finished Product

Stability data on the finished product in the proposed packaging have been provided in accordance with EU guidelines and support the shelf-life and storage conditions listed in sections 6.3 and 6.4 of the SmPC.

II.4 Discussion on Chemical and Pharmaceutical Aspects

The important quality characteristics of the product are well-defined and controlled. Satisfactory chemical and pharmaceutical documentation has been provided, assuring consistent quality of Prucalopride 1 mg and 2 mg film-coated tablets.

III. NON-CLINICAL ASPECTS

III.1 Introduction

This active substance is a generic formulation of Resolor 1mg and 2mg film-coated tablets film-coated tablets marketed by Shire Pharmaceuticals Ireland Limited, authorised by a centralised procedure EMEA/H/C/001012 on the European market. No new preclinical data have been submitted. As such, no pre-clinical assessment has been made on the application. This is acceptable for this type of application.

IV. CLINICAL ASPECTS

IV.1 Introduction

Prucalopride is a well known active substance with established efficacy and tolerability.

The content of the SmPC approved during the decentralised procedure is in accordance with that accepted for the reference product Resolor 1mg and 2mg film-coated tablets film-coated tablets marketed by Shire Pharmaceuticals Ireland Limited.

For this generic application, no bioequivalence studies have been submitted.

A waiver for all in vivo bioequivalence studies was requested for both strengths.
Based on its high solubility and permeability, Prucalopride 1 mg & 2 mg film-coated tablets can be categorized as a BCS Class 1. The drug product is an immediate-release oral dose form with systemic action, and the drug product is a dosage form that is pharmaceutically equivalent to the reference product. As required for a BCS-based biowaver, the drug substance has known human absorption (>90%) and is not considered to have a narrow therapeutic index.

It is agreed there are no differences in excipients or coating in the formulation compared to the reference product that might affect bioavailability.

The applicant's justification for a BCS-based biowaver exemption for in vivo bioequivalence studies meets the criteria detailed in EMA guideline on the investigation of bioequivalence and is accepted. Prucalopride 1 and 2 mg film-coated tablets can be considered therapeutic equivalent to the reference formulation.

IV.2 Pharmacokinetics
No new data were provided. This is acceptable for this type of application.

IV.3 Pharmacodynamics

No new data were provided. This is acceptable for this type of application.

IV.4 Clinical Efficacy

No new data were provided. This is acceptable for this type of application.

IV.5 Clinical Safety

No new data were provided. This is acceptable for this type of application.

Risk Management Plan
The applicant has submitted a risk management plan, in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Prucalopride 1mg and Prucalopride 2mg film coated tablets. The RMP (version 0.3, dated 31/01/20) is acceptable. Routine risk minimization activities are considered sufficient. The applicant is requested to ensure it maintains the RMP in line with the latest SmPC updates and maintains regular reviews.

With regard to PSUR submission, the MAH should take the following into account:
• PSURs shall be submitted in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal. Marketing authorisation holders shall continuously check the European medicines webportal for the DLP and frequency of submission of the next PSUR.

IV.6 Discussion on the clinical aspects

Prucalopride 1mg & Prucalopride 2mg Film-coated Tablet is a generic form of Resolor 1mg and 2mg film-coated tablets.
Resolor 1mg and 2mg film-coated tablets is a well-known medicinal product with a proven chemical-pharmaceutical quality and an established favourable efficacy and safety profile.

A waiver for all in vivo bioequivalence studies was requested for both strengths. The applicant's justification for a BCS-based biowaver exemption for in vivo bioequivalence studies meets the criteria detailed in EMA guideline on the investigation of bioequivalence and is accepted. Prucalopride 1 and 2 mg film-coated tablets can be considered therapeutic equivalent to the reference formulation.

The SmPC is consistent with that of the reference product.

V. OVERALL CONCLUSIONS

Prucalopride 1mg & Prucalopride 2mg Film-coated Tablet is a generic form of Resolor 1mg and 2mg film-coated tablets. Resolor 1mg and 2mg film-coated tablets is a well-known medicinal product with a proven chemical-pharmaceutical quality and an established favourable efficacy and safety profile.

Bioequivalence has been shown to be in compliance with the CHMP guidance documents. The SmPC is consistent with that of the reference product.

The MAH has provided written confirmation that systems and services are in place to ensure compliance with their pharmacovigilance obligations.

The HPRA, on the basis of the data submitted considered that Prucalopride 1mg & Prucalopride 2mg Film-coated Tablet demonstrated bioequivalence with the reference product as well as a satisfactory risk/benefit profile and therefore granted a marketing authorisation.

VI. REVISION DATE

August 2021

VII. UPDATES

SCOPE	PROCEDURE NUMBER	PRODUCT INFORMATION AFFECTED	DATE OF START OF PROCEDURE	DATE OF END OF PROCEDURE
MAH transfer	CRN00CJGT	SmPC section 7, 8, 10 Package Leaflet New MA Holder: Pinewood Laboratories Ltd New PA number: PA0281/260/001	N/A	27/08/2021